Lack Of Detectable Platelet Autoantibodies Is Correlated With Nonresponsiveness To Rituximab Treatment In Itp Patients

Leendert Porcelijn,Elly Huiskes,Martin Schipperus,Bronno Van Der Holt,Masja De Haas,Jaap Jan Zwaginga

BLOOD（2017）

引用 29|浏览13

暂无评分

摘要

To the editor:Rituximab, a chimeric CD20 monoclonal antibody that causes depletion of B cells, shows short-term treatment efficacy in 40% to 60% of immune thrombocytopenia (ITP) patients.[1][1],[2][2] Our recently published multicenter randomized open-label phase 2 trial comparing 3 rituximab

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要